Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Adicet Bio, Inc. Director's Dealing 2020

Sep 18, 2020

34412_dirs_2020-09-17_2e02d835-f918-47b8-af3f-7fad00862611.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Adicet Bio, Inc. (ACET)
CIK: 0001720580
Period of Report: 2020-09-15

Reporting Person: ABBOT STEWART (See Remarks)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2020-09-15 Employee Stock Option (right to buy) $2.26 A 84791 Acquired 2028-08-14 Common Stock (84791) Direct
2020-09-15 Employee Stock Option (right to buy) $5.97 A 57151 Acquired 2029-10-15 Common Stock (57151) Direct
2020-09-17 Incentive Stock Option (right to buy) $16.11 A 63751 Acquired 2030-09-17 Common Stock (63751) Direct

Footnotes

F1: 25% of the option vested on June 27, 2019, and 1/36th of the remaining unvested option vests on each of the next thirty-six (36) monthly anniversaries thereafter, provided that Dr. Abbot remains in continuous service as of the applicable vesting date.

F2: Received in exchange for an employee stock option to acquire 683,800 shares of common stock of Adicet Bio, Inc., a Delaware corporation ("Old Adicet"), for $0.280 per share in connection with the merger (the "Merger") of Old Adicet with and into Project Oasis Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of resTORbio, Inc., a Delaware corporation ("resTORbio"). On the effective date of the Merger, resTORbio changed its name to "Adicet Bio, Inc."

F3: 1/48th of the option vests on each of the forty-eight (48) monthly anniversaries of October 15, 2019, provided that Dr. Abbot remains in continuous service as of the applicable vesting date.

F4: Received in exchange for an employee stock option to acquire 460,900 shares of common stock of Old Adicet for $0.740 per share in connection with the Merger.

F5: 1/48th of the shares of common stock subject to the option shall vest on each of the forty-eight (48) monthly anniversaries of the vesting commencement date, provided that Dr. Abbot remains in continuous service as of the applicable vesting date.